STAT-Diagnostica disclosed the conclusion of its Series B growth financing round that earned an estimated amount of US$22 million or EUR17 million. New investor Kurma Life Sciences Partner led the financing round. Other new investors like Boehringer Ingelheim Venture Fund, Caixa Capital Risc and Idinvest also participated, including existing investors Axis and Ysios Capital, who notably increased its investment. At present Ysios is the largest shareholder at STAT-Diagnostica.

Commenting on its increased investment, Investment Director of Ysios Capital, Raul Martin-Ruiz said, "When we invested in STAT-Diagnostica in June 2011, the company was almost just an idea. Within two years, STAT-Diagnostica has achieved pre-commercial validation of the technology, which has reduced the technological risks significantly, and has successfully raised the interest of specialized international investors. We are very satisfied to have played a relevant role building up the investors syndicate."

"The Series B financing is a significant milestone that will support our preparation for a European market launch in 2015," according to the co-founder and CEO of STAT-Diagnostica, Jordi Carrera.

He further  disclosed, "Our ability to close the round is proof of the outstanding team behind the company, and demonstrates the potential of our technology in the fast growing decentralized diagnostics market."

The Barcelona Science Park based STAT-Diagnostica was founded in 2010. It developed a Near Patient Testing System that will make things easier at a shorter processing time which will draw diagnostic results regarding a certain medical condition.